We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports: UnitedHealth, PepsiCo, Amgen & More
Read MoreHide Full Article
Tuesday, August 14, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 12 major stocks, including UnitedHealth (UNH - Free Report) , PepsiCo (PEP - Free Report) and Amgen (AMGN - Free Report) . These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
Buy-rated UnitedHealth's shares have outperformed the Zacks Medical Insurance industry's rally over the past year (up +34.2% vs. +33.8%). UnitedHealth Group’s earnings surpassed expectations and increased year over year. Higher revenues, strength in both segments — UnitedHealthcare and Optum — plus membership growth led to this outperformance. The Zacks analyst thinks the company's robust Government business and continued strong performance at Optum are driving long-term growth. Its international business and strong capital position are the other positives. The company has been witnessing an increase in membership over the past many years. It once again raised its 2018 earnings guidance, buoying optimism among investors in the stock. However, the company is witnessing membership pressure in its commercial business. Increasing consolidation will also heat up competition in the industry.
Shares of PepsiCo have gained +16.8% in the past three months, outperforming the Zacks Soft Beverages industry's rally of +8.1%, driven by a solid earnings trend with beat recorded in the last 10 quarters. Strong performances in its international division, primarily higher revenue growth in developing and emerging markets, have been aiding results. The company has reported positive sales surprise in six of the last eight quarters. The Zacks analyst thinks the company is also gaining from significant strength in the snacks business, which has mostly offset the sluggishness in beverage category. Moreover, the company’s product innovations to include healthier food assortments and non-carbonated drinks in its portfolio should boost sales. However, consumers’ awareness on health and wellness, alongside new taxes on sugar-sweetened beverages and growing regulatory pressures are affecting CSD sales.
Amgen’s shares have gained +12.5% year to date versus the Zacks Biomedical and Genetics industry's decline of -5.4%. Amgen beat expectations for both earnings and sales in second-quarter 2018 and also raised the full-year expectations. The Zacks analyst thinks the Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Repatha, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the recent approval of migraine candidate Aimovig was a huge boost. However, Amgen has some challenges in store, given the slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions.
Other noteworthy reports we are featuring today include Mylan , Textron (TXT - Free Report) and ABB Ltd .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Note: Our Director of Research Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports: UnitedHealth, PepsiCo, Amgen & More
Tuesday, August 14, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 12 major stocks, including UnitedHealth (UNH - Free Report) , PepsiCo (PEP - Free Report) and Amgen (AMGN - Free Report) . These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-rated UnitedHealth's shares have outperformed the Zacks Medical Insurance industry's rally over the past year (up +34.2% vs. +33.8%). UnitedHealth Group’s earnings surpassed expectations and increased year over year. Higher revenues, strength in both segments — UnitedHealthcare and Optum — plus membership growth led to this outperformance. The Zacks analyst thinks the company's robust Government business and continued strong performance at Optum are driving long-term growth. Its international business and strong capital position are the other positives. The company has been witnessing an increase in membership over the past many years. It once again raised its 2018 earnings guidance, buoying optimism among investors in the stock. However, the company is witnessing membership pressure in its commercial business. Increasing consolidation will also heat up competition in the industry.
(You can read the full research report on UnitedHealth here >>>).
Shares of PepsiCo have gained +16.8% in the past three months, outperforming the Zacks Soft Beverages industry's rally of +8.1%, driven by a solid earnings trend with beat recorded in the last 10 quarters. Strong performances in its international division, primarily higher revenue growth in developing and emerging markets, have been aiding results. The company has reported positive sales surprise in six of the last eight quarters. The Zacks analyst thinks the company is also gaining from significant strength in the snacks business, which has mostly offset the sluggishness in beverage category. Moreover, the company’s product innovations to include healthier food assortments and non-carbonated drinks in its portfolio should boost sales. However, consumers’ awareness on health and wellness, alongside new taxes on sugar-sweetened beverages and growing regulatory pressures are affecting CSD sales.
(You can read the full research report on PepsiCo here >>>).
Amgen’s shares have gained +12.5% year to date versus the Zacks Biomedical and Genetics industry's decline of -5.4%. Amgen beat expectations for both earnings and sales in second-quarter 2018 and also raised the full-year expectations. The Zacks analyst thinks the Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Repatha, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the recent approval of migraine candidate Aimovig was a huge boost. However, Amgen has some challenges in store, given the slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions.
(You can read the full research report on Amgen here >>>).
Other noteworthy reports we are featuring today include Mylan , Textron (TXT - Free Report) and ABB Ltd .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Note: Our Director of Research Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>